Document is current
Any future updates will be listed below
-
Authors
Kauer, Joseph https://orcid.org/0000-0003-1632-0167
Hörner, Sebastian
Osburg, Lukas
Müller, Stefanie
Märklin, Melanie
Heitmann, Jonas S
Zekri, Latifa
Rammensee, Hans-Georg
Salih, Helmut R
Jung, Gundram
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04104607 at ClinicalTrials.govDocuments that mention this clinical trial
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
https://doi.org/10.1136/jitc-2021-003655
Clinical development of the bispecific PSMAxCD3 antibody CC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.2534
1298 Two targets, two signals: combinatorial cancer therapy with bispecific antibodies directed to CD3 and CD28 improves specificity and prevents T-cell exhaustion
https://doi.org/10.1136/jitc-2024-sitc2024.1298
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma (Pre-results)
https://doi.org/10.1136/bmjopen-2020-039639
Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.2536
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
https://doi.org/10.1136/jitc-2020-000621
-
Funding
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2007.115.3)
Deutsche Krebshilfe (111828)
Deutsche Krebshilfe (70112914)
Helmholtz Validation Fund (OPTIMAB)
Deutsche Forschungsgemeinschaft (SA1360/7-3)
Deutsche Forschungsgemeinschaft (SA1360/9-1)
Germany's Excellence Strategy (EXC 2180/1)
Deutschen Konsortium für Translationale Krebsforschung
- License Information
